Navigation Links
Circassia Acquires North American and Japanese Rights to Dopexamine
Date:10/8/2008

examine is not approved for use currently in the US, Canada or Japan.

"ToleroCare has great potential to dramatically improve patients' recovery following major surgery, as well as to significantly reduce costs by shortening the time spent in hospital. With approximately 825,000 high-risk surgical procedures carried out each year in the US, and the high cost associated with hospital stays, ToleroCare is targeting a major market opportunity," said Steve Harris, Circassia's CEO. "Dopexamine provides Circassia with a further phase II clinical-stage development programme that fits well with our outsourced business model. By establishing a commercial-scale supply chain for dopexamine, we are well positioned to rapidly progress ToleroCare to market."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, which includes Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune(R). The company is also developing its ToleroTrans(R) organ anti-rejection technology, which uses a similar approach to down-regulate immune responses in transplant patients. Circassia has a number of ongoing development programmes, with the most advanced against cat-dander allergy in phase II clinical testing.
For more information please visit http://www.circassia.co.uk.

Contacts

Steve Harris Rob Budge

CEO RJB Communications

Circassia Tel: +44(0)1865-7609
'/>"/>

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
2. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
3. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
4. Neogen Acquires Kane Enterprises
5. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
6. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
7. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
8. NSF International Acquires David Begg Associates
9. United BioSource Acquires Caro Research, Leader in Simulation Modeling
10. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
11. Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
(Date:9/18/2014)... Sept. 18, 2014  U.S. biotech company Kultevat ... exclusive license for technology developed by the Donald ... in plants, including for applications in production of natural ... The technology was developed under the direction of ... and former president of the Danforth Plant Science Center, ...
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 ... en 1974, a été depuis 40 ... les évaluations cliniques traditionnelles par des évaluations ... et sur les impacts économiques des traitements. ... A cours d,une récente ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... Agencourt offers primer walking sequencing of PCR products, plasmid inserts , ... in either raw or , purified form and ... Select from either single stranded coverage for confirmation sequencing , ... purposes. , ...
... , , ... sequence delineation on capillary electrophoresis, instrumentation. CleanSEQ has ... system with the, ABI 3700 and 3730xl sequencers. ... prone to evaporation and exposure to, air before ...
... , Agencourts RNAClean kit provides a ... purifying nucleic acid products generated in common enzymatic , ... formatted for microarray , gene expression analysis experiments ... automated formats. RNAClean eliminates the need for vacuum filtration or , ...
Cached Biology Technology:Primer Walking 2CleanSEQ on the ABI 3100 2CleanSEQ on the ABI 3100 3CleanSEQ on the ABI 3100 4RNAClean - RNA & cDNA in vitro Reaction Purification 2
(Date:9/18/2014)... to acquire and creatively manipulate spoken language is unique ... past 6 million years of human evolution to make ... best candidate gene we now have," says Wolfgang Enard, ... his efforts to understand the molecular biological basis of ... The results of his latest study, undertaken in collaboration ...
(Date:9/18/2014)... happy-go-lucky characters, so you might expect that most would ... fact some dogs are distinctly more pessimistic than others, ... "This research is exciting because it measures positive and ... offers researchers and dog owners an insight into the ... Melissa Starling, from the Faculty of Veterinary Science. Her ...
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3How stress tears us apart 2
... For Immediate Release A group of researchers at ... Institute has published a paper that reviews new strategies ... whether people are predisposed to developing common conditions like ... age, the entire DNA sequences, or "genomes," of humans ...
... immune cell that directs other cells to fight infection ... in both health and disease. Researchers from the University ... stimulatory molecule and a protein found on the membrane ... multi-taskers of sorts. Th17 cells protect the body against ...
... ARLINGTON, Va. - To expand collaboration and initiatives, the ... be held Nov. 8-10, will explore a wide range ... explosive devices. Hosted by the Office of Naval ... Hyatt Regency in Crystal City, Va., and will feature ...
Cached Biology News:Scientists describe new approach for identifying genetic markers for common diseases 2Scientists describe new approach for identifying genetic markers for common diseases 3Penn study shows 2-sided immune cell could be harnessed to shrink tumors 2
Request Info...
Candida (IgG) -Ab EIA Sample Size: 5 l...
... Oxidized LDL (Competitive) EIA Principle: The ... monoclonal antibody 4E6. Oxidized LDL in the sample ... bound to the microtiter well for the binding ... washing st Sample Size: 25 l ...
... used with its manganese-containing reaction buffer, converts ... of short (1825 bp) interfering RNAs (siRNA) ... 1.3 units (1 l) of ShortCut RNase ... of dsRNA into siRNA suitable for RNA ...
Biology Products: